Related Experiment Video

Updated: Mar 22, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

24.8K

Australian recommendations for the management of hepatitis C virus infection: a consensus statement

Alexander J V Thompson1

  • 1Department of Gastroenterology, St Vincent's Hospital, Melbourne, VIC alexander.thompson@svha.org.au.

The Medical Journal of Australia
|April 15, 2016
PubMed

Insights

Hepatitis C virus (HCV) infection is curable for all Australians. New antiviral therapies are available on the Pharmaceutical Benefits Scheme (PBS) for genotypes 1-6, offering effective treatment options.

Area of Science:

  • Hepatology
  • Infectious Diseases
  • Pharmacology

Background:

  • Chronic hepatitis C virus (HCV) infection impacts 230,000 Australians.
  • HCV infection poses risks of liver fibrosis, cirrhosis, liver failure, and hepatocellular carcinoma.
  • HCV infection is curable, necessitating consideration for antiviral therapy for all affected individuals.

Purpose of the Study:

  • To outline current antiviral treatment guidelines for chronic HCV infection in Australia.
  • To inform healthcare providers about Pharmaceutical Benefits Scheme (PBS) listed therapies.
  • To highlight key considerations for pre-treatment assessment and specialist referral.

Main Methods:

  • Review of current HCV treatment guidelines and Pharmaceutical Benefits Scheme (PBS) listings.
  • Description of available interferon-free and interferon-based antiviral regimens.
  • Identification of patient populations requiring specialist care.

Main Results:

  • Interferon-free regimens (sofosbuvir, ledipasvir, daclatasvir, ribavirin) are available for HCV genotypes 1-3.
  • Treatment for genotypes 4-6 involves sofosbuvir, peginterferon-alfa, and ribavirin.
  • PBS listing enables specialist or GP-consulted prescription of these therapies.

Conclusions:

  • All Australians with HCV infection should be assessed for antiviral therapy.
  • Pre-treatment evaluation must include HCV genotype, cirrhosis assessment, and drug interaction screening.
  • Specialist referral is crucial for patients with cirrhosis or other complex conditions.

More Related Videos

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.8K
A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

10.4K

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
27
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
740
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
612
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
467
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
4
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
50.5K